Inflammatory rheumatic disorders and bone

Current Rheumatology Reports

Volumn 14, Issue 3, 2012, Pages 224-230

  Bultink, Irene E M ^a   Vis, Marijn ^b   Van Der Horst Bruinsma, Irene E ^a   Lems, Willem F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Ankylosing spondylitis; Bone; Fractures; Inflammation; Metabolic bone disease; Osteoporosis; Rheumatoid arthritis; SLE; Systemic lupus erythematosus

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

AGE; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE DISEASE; BONE EROSION; BONE MASS; DISEASE ACTIVITY; DRUG MEGADOSE; FRACTURE; FRAGILITY FRACTURE; HUMAN; INFLAMMATORY RHEUMATIC DISEASE; LIFESTYLE MODIFICATION; METABOLIC BONE DISEASE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING;

EID: 84860750808     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0252-8     Document Type: Article

References (65)

1. Kalla AA, Fataar AB, Jessop SJ, et al. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum. 1993;36:1726-34. (Pubitemid 23360013)
2. Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14:106-12. (Pubitemid 40327660)
3. Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol. 2003;22:318-23. (Pubitemid 37483628)
4. Uaratanawong S, Deesomchoke U, Lertmaharit S, et al. Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol. 2003;30:2365-8. (Pubitemid 37413894)
5. • Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res. 2012;1:2-8. This is an outstanding overview on the multifactorial pathogenesis of osteoporosis and fractures in SLE.
6. Almehed K, Forsblad DH, Kvist G, et al. Prevalence and risk factors of osteoporosis in female SLE patients: extended report. Rheumatology (Oxford). 2007;46:1185-90. (Pubitemid 47050627)
7. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res. 1995;8:137-45.
8. Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;54:2044-50. (Pubitemid 40994328)
9. Lakshminarayanan S, Walsh S, Mohanraj M, et al. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102-8. (Pubitemid 32062031)
10. Yee CS, Crabtree N, Skan J, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:111-3. (Pubitemid 40075285)
11. Lee C, Almagor O, Dunlop DD, et al. Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus. Arthritis Rheum. 2007;57:585-92. (Pubitemid 46764047)
12. Fangtham M, Petri M. Predictors of osteoporotic fracture in SLE [abstract]. Arthritis Rheum. 2009;60(Suppl):S110.
13. Svenungsson E, Fei GZ, Jensen-Urstad K, et al. TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus. 2003;12:454-61. (Pubitemid 36830119)
14. Frostegard J, Svenungsson E, Wu R, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 2005;52:192-200. (Pubitemid 40129248)
15. Moerman EJ, Teng K, Lipschitz DA, et al. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell. 2004;3:379-89. (Pubitemid 40246708)
16. Teichmann J, Lange U, Stracke H, et al. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int. 1999;18:137-40.
17. Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, et al. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol. 2009;28:579-85.
18. Lee C, Almagor O, Dunlop DD, et al. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford). 2006;45:53-60. (Pubitemid 43033875)
19. Borba VZ, Vieira JG, Kasamatsu T, et al. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int. 2009;20:427-33.
20. Huisman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol. 2001;28:2535-9. (Pubitemid 33031987)
21. Toloza SM, Cole DE, Gladman DD, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010;19:13-9.
22. Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008;47:920-3. (Pubitemid 351796385)
23. Formiga F, Moga I, Nolla JM, et al. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol. 1997;15:387-92. (Pubitemid 27324000)
24. Jardinet D, Lefebvre C, Depresseux G, et al. Longitudinal analysis of bone mineral density in premenopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford). 2000;39:389-92. (Pubitemid 30307324)
25. Kipen Y, Briganti E, Strauss B, et al. Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol. 1999;26:310-7. (Pubitemid 29066734)
26. Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999;42:882-90. (Pubitemid 29214998)
27. Lee C, Almagor O, Dunlop DD, et al. Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol. 2007;34:2018-23. (Pubitemid 47548204)
28. Li EK, Tam LS, Griffith JF, et al. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol. 2009;36:1646-52.
29. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Review. Nat Rev Rheumatol. 2009;5:667-76.
30. Lacey DL, Timms, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-76. (Pubitemid 28180851)
31. • Geusens PP, Lems WF. Osteoimmunology and osteoporosis. Arthritis Res Ther. 2011;13(5):242. Epub. This is a large overview on osteoimmunology in rheumatic diseases.
32. •• Schett G, Saag KG, Bijlsma JWJ. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis. 2010;69:1415-9. This is an outstanding state-of-the-art article on bone biology.
33. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in RA. Arthritis Rheum. 2008;58:1299-309.
34. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276-87.
35. Lories RJ, Luyten FP. Osteoimmunology: Wnt antagonists: for better or worse? Nat Rev Rheumatol. 2009;5:420-1.
36. Garnero P, Tabassi NC, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol. 2008; 35:2313-5.
37. Terpos E, Fragidaki K, Konsta M, et al. Early effects of Il-6 receptor inhibition on bone homeostasis. Clin Exp Rheumatol. 2011;29:921-5.
38. Xu S, Wang Y, Lu J, Xu. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int. 2011.
39. Schett G, Stach C, Zwerina J, et al. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008;58:2936-48.
40. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:522-30.
41. Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 1994;8914:23-7. (Pubitemid 24199420)
42. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with Infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495-9. (Pubitemid 44629129)
43. Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YP, et al. Changes in hand and generalized bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68: 330-6.
44. Dirven L, Güler-Yüksel M, de Beus WM, et al. Changes in hand bone mineral density and the association with the level of disease activity in patients with RA. Arthritis Care Res. 2011:1691-9.
45. Spector TD, Hall GM, McCloskey EV, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ. 1993;306:558. (Pubitemid 23056878)
46. Huusko TM, Korpela M, Karppi P, et al. Threefold increased risk of hip fractures with rheumatoid arthritis in central Finland. Ann Rheum Dis. 2001;60:521-2. (Pubitemid 32417428)
47. van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104-12.12.
48. •• Roux C. Osteoporosis in inflammatory joint diseases. Osteoporosis Int. 2011;22:412-23. This is an elegant overview, predominantly on clinical data regarding osteoporosis and rheumatic diseases.
49. Vis M, Haavardsholm EA, Bøyesen P, et al. High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int. 2011;22:2413-9.
50. S. Amin, S. Gabriel, S. Achenbach et al. Fracture risk is increased in young women with rheumatoid arthritis. J Bone Miner Res. 2011;26(Suppl 1).
51. Cooper C, Carbone L, Michet CJ, et al. Fracture risk in patients with AS: a population based study. J Rheumatol. 1994;10:1887-82.
52. Vosse D, Landewé R, van der Heijde D, et al. AS and the risk of fracture: results from a large primary care based nested case- control study. Ann Rheum Dis. 2009;68:1839-42.
53. Vosse D, Feldtkeller E, Erlendsson, et al. Clinical vertebral fractures in patients with AS. J Rheumatol. 2004;10:1981-5.
54. Franck H, Meurer T, Hofbauer LC, et al. Evaluation of BMD, hormones, biochemical markers of bone metabolism, and OPG serum levels in patients with AS. Rheumatol. 2004;31:2236-41. (Pubitemid 39453245)
55. Arends SA, Spoorenberg A, Bruyn GA, et al. The relationship between BMD, vitamin D levels and bone markers in AS patients. Osteoporos Int. 2011;22:1431-9.
56. Lee YS, Schlotzhauer T, Ott SM, et al. Skeletal status of men with early and late AS. Am J Med. 1997;103:233-41. (Pubitemid 27413406)
57. Karberg K, Zochling J, Sieper J, et al. Bone loss is detected more frequently in patients with AS with syndesmophytes. J Rheumatol. 2005;32:1290-8. (Pubitemid 40995385)
58. van der Weijden MA, van Denderen JC, Lems WF, et al. Low BMD is related to male gender and decreased functional capacity in early AS. Clin Rheumatol. 2011;30:497-503.
59. van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, et al. High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int. 2011; Epub.
60. Allali F, Breban M, Porcher R, et al. Increase in BMD of patients with AS treated with anti-TNF. Ann Rheum Dis. 2003;62:347-9.
61. Maksymowych WP, Chiochanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on MRI predict the development of new syndesmophytes in AS. Arthritis Rheum. 2009;60:93-102.
62. Schett G, Independent development of inflammation and new bone formation in ankylosing spondylitis. Arthritis Rheum. 2012, Epub.
63. Zhang J, Saag KG, Curtis JR. Longterm safety concerns of antiresorptive therapy. Rheum Dis Clin North America. 2011;37:387-400.
64. Patlas N, Colomb G, Yaffe P, et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60:68-73. (Pubitemid 29397194)
65. Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for longterm treatment of glucocorticoid induced osteoporosis. Arthritis Rheum. 2011;63:325-8.